172 related articles for article (PubMed ID: 25754431)
1. Public Drug Coverage and Its Impact on Triptan Use Across Canada: A Population-Based Study.
Amadio A; Lee K; Yao Z; Camacho X; Knowles S; Lay C; Paterson JM; Hunt J; Gomes T;
Headache; 2015; 55 Suppl 4():212-20. PubMed ID: 25754431
[TBL] [Abstract][Full Text] [Related]
2. Triptans use and overuse: A pharmacoepidemiology study from the French health insurance system database covering 4.1 million people.
Braunstein D; Donnet A; Pradel V; Sciortino V; Allaria-Lapierre V; Lantéri-Minet M; Micallef J
Cephalalgia; 2015 Nov; 35(13):1172-80. PubMed ID: 25667299
[TBL] [Abstract][Full Text] [Related]
3. Triptan use in Italy: Insights from administrative databases.
Da Cas R; Nigro A; Terrazzino S; Sances G; Viana M; Tassorelli C; Nappi G; Cargnin S; Pisterna A; Traversa G; Genazzani AA
Cephalalgia; 2015 Jun; 35(7):619-26. PubMed ID: 25246521
[TBL] [Abstract][Full Text] [Related]
4. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
[TBL] [Abstract][Full Text] [Related]
5. Variation in Prescription Drug Coverage for Triptans: Analysis of Insurance Formularies.
Minen MT; Lindberg K; Langford A; Loder E
Headache; 2017 Sep; 57(8):1243-1251. PubMed ID: 28691382
[TBL] [Abstract][Full Text] [Related]
6. Triptan persistency among newly initiated users in a pharmacy claims database.
Katić BJ; Rajagopalan S; Ho TW; Chen YT; Hu XH
Cephalalgia; 2011 Mar; 31(4):488-500. PubMed ID: 20937605
[TBL] [Abstract][Full Text] [Related]
7. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
[TBL] [Abstract][Full Text] [Related]
8. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Holland S; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
J Neurol Sci; 2013 Mar; 326(1-2):10-7. PubMed ID: 23394974
[TBL] [Abstract][Full Text] [Related]
9. Triptan overuse in the Dutch general population: a nationwide pharmaco-epidemiology database analysis in 6.7 million people.
Dekker F; Wiendels NJ; de Valk V; van der Vliet C; Knuistingh Neven A; Assendelft WJ; Ferrari MD
Cephalalgia; 2011 Jun; 31(8):943-52. PubMed ID: 21593190
[TBL] [Abstract][Full Text] [Related]
10. Triptans for Acute Migraine: Drug Class Review to Help Inform Policy Decisions.
Knowles S; Oh P; Gomes T;
Headache; 2015; 55 Suppl 4():191-8. PubMed ID: 26178586
[TBL] [Abstract][Full Text] [Related]
11. Use and overuse of triptans in Austria - a survey based on nationwide healthcare claims data.
Zebenholzer K; Gall W; Wöber C
J Headache Pain; 2018 May; 19(1):34. PubMed ID: 29777424
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
Christie SN; Giammarco R; Gawel M; Mackie G; Gladstone J; Becker WJ
Can J Neurol Sci; 2010 Sep; 37(5):588-94. PubMed ID: 21059503
[TBL] [Abstract][Full Text] [Related]
13. Patterns of use and health expenses associated with triptans among adults with migraines.
Wu J; Noxon V; Lu ZK
Clin J Pain; 2015 Aug; 31(8):673-9. PubMed ID: 25185875
[TBL] [Abstract][Full Text] [Related]
14. Identifying the factors underlying discontinuation of triptans.
Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
[TBL] [Abstract][Full Text] [Related]
15. Effects of switching acute treatment on disability in migraine patients using triptans.
Serrano D; Buse DC; Kori SH; Papapetropoulos S; Cunanan CM; Manack AN; Reed ML; Lipton RB
Headache; 2013 Oct; 53(9):1415-29. PubMed ID: 23808937
[TBL] [Abstract][Full Text] [Related]
16. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
[TBL] [Abstract][Full Text] [Related]
17. Results of a 2-year retrospective cohort study of newly prescribed triptan users in European nationwide practice databases.
Ng-Mak DS; Chen YT; Ho TW; Stanford B; Roset M
Cephalalgia; 2012 Sep; 32(12):875-87. PubMed ID: 22833612
[TBL] [Abstract][Full Text] [Related]
18. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
[TBL] [Abstract][Full Text] [Related]
19. Migraine burden and costs in France: a nationwide claims database analysis of triptan users.
Donnet A; Emery C; Aly S; Allaf B; Cayre F; Mahieu N; Gourmelen J; Levy P; Fagnani F
J Med Econ; 2019 Jul; 22(7):616-624. PubMed ID: 30836035
[No Abstract] [Full Text] [Related]
20. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
